By analyzing HER2 expression and clinicopathological features, we found that HER2 had higher expression in T1 stage, high‐grade and recurrent tumor tissues than in Ta stage, low‐grade and initial tumor tissues (p < 0.01, p < 0.01, and p < 0.05, respectively, Figure 1b). This evidence concerns the gene ERBB2 and neoplasm.